Peregrine's corporate office is located in Tustin, California.
Peregrine Pharmaceuticals, Inc.
14282 Franklin Avenue
Tustin, CA 92780
When was Peregrine founded?
Peregrine was founded in June 3, 1981 under its former name Techniclone International Corporation, a California corporation. On March 24, 1997, Techniclone International Corporation was merged with and into Techniclone Corporation, a corporation incorporated in the State of Delaware on September 25, 1996. This merger was effected for the purpose of effecting a change in the Company's state of incorporation from California to Delaware. The Company changed its name from Techniclone Corporation to Peregrine Pharmaceuticals, Inc. in October 2000.
When and where was Peregrine incorporated?
Peregrine was incorporated in the State of Delaware on September 25, 1996.
Who is Peregrine's outside legal counsel?
Peregrine's outside legal counsel is Snell & Wilmer, LLP.
Snell & Wilmer, L.L.P.
600 Anton Blvd., Ste. 1400
Costa Mesa, CA 92626-7689
Phone: 714-427-7000
Fax: 714-427-7799 www.swlaw.com
Who are Peregrine's independent auditors?
Peregrine's independent auditors are Ernst & Young LLP.
Ernst & Young LLP
18111 Von Karman Avenue, Suite 1000
Irvine, CA 92612
How can I contact Peregrine?
Please refer to our Contact Us page or contact our investor relations directly at (800)987-8256.
When did Peregrine acquire the rights to the VTA technology?
On April 24, 1997, the Company acquired all of the outstanding stock of Vascular Targeting Technologies, Inc. (formerly known as Peregrine Pharmaceuticals, Inc.) in exchange for 5,080,000 shares of the Company's common stock and the assumption of net liabilities of approximately $484,000. Vascular Targeting Technologies, Inc. was a development stage company involved in the research and development of vascular targeting agents. The acquisition was accounted for as a purchase. The excess of the purchase price over net tangible assets acquired (cash and notes receivable) and liabilities assumed (accounts payable and accrued liabilities) represents the difference between the fair value of the Company's common stock exchanged and the fair value of net assets purchased. The excess purchase price of $27,154,402 over the net tangible assets acquired represents the amount paid for acquired technologies and related intangible assets. The excess purchase price for the acquisition had been charged to operations as of the effective date of the acquisition as the related technologies have not reached technological feasibility and the technology had no known future alternative uses other than the possibility for treating cancer patients.
When did Peregrine acquire the rights to the TNT technology?
On January 18, 1994, Peregrine and Cancer Biologics, Inc. ("CBI") entered into an Agreement and Plan of Merger (the "Agreement and Plan of Merger") which contemplated the merger of CBI with and into Peregrine. On June 10, 1994, the shareholders of the Company approved the merger pursuant to the Agreement and Plan of Merger. The merger between CBI and the Company was completed on July 26, 1994. The assets of CBI acquired by the Company consist primarily of research and development of the TNT antibody technology. As a result of the merger, the Company incurred an immediate charge to operations for purchased in-process research and development of approximately $4,850,000. This amount represents the excess of the fair market value of the Company's common stock issued over the net assets acquired of CBI, plus an additional non-recurring charge relating to CBI stock options assumed by the Company.
Do you have another question that hasn't been answered?
Please submit your question using the form below. Fields marked with an * are required.
Investor FAQs
What is the ticker symbol for Peregrine Pharmaceuticals, Inc.?
Peregrine is traded on the NASDAQ Capital Markets.
What is your stock CUSIP Number?
The CUSIP Number for the Peregrine Pharmaceuticals, Inc. Common Stock is 713661 10 6.
Does Peregrine issue dividends?
No. Peregrine does not currently issue dividends.
Does Peregrine have a direct stock purchase plan?
No. Peregrine does not currently have a direct stock purchase plan. Shares can only be traded through your stock brokerage firm.
Who is Peregrine's Transfer Agent?
Integrity Stock Transfer
3265 E. Warm Spring Rd.
Las Vegas, NV 89120
Telephone: (702) 317-7757
Toll Free: (877) 317-7757
Fax: (702) 796-5650
Email: stock@integritynevada.net
How do I change my address or the title on the Peregrine stock certificates?
All questions regarding stock certificates, change of address, consolidation of accounts, transfer of ownership and other related stock account matters should be addressed directly to our Transfer Agent.
Integrity Stock Transfer
3265 E. Warm Spring Rd.
Las Vegas, NV 89120
Telephone: (702) 317-7757
Toll Free: (877) 317-7757
Fax: (702) 796-5650
Email: stock@integritynevada.net
How can I replace my lost stock certificates?
Please contact our Transfer Agent.
Integrity Stock Transfer
3265 E. Warm Spring Rd.
Las Vegas, NV 89120
Telephone: (702) 317-7757
Toll Free: (877) 317-7757
Fax: (702) 796-5650
Email: stock@integritynevada.net
When did Peregrine go public?
Peregrine's initial public offering was on December 16, 1982.
When has Peregrine had stock splits?
In October 2008, Peregrine's shareholders approved a 1-for-5 reverse stock split that became effective in October 2009. The reverse stock split entitled each shareholder of record at the close of business on October 16, 2009 to receive 1 share of common stock in exchange for every 5 shares of common stock held. For more information, please click here.
In December 1986, the shareholders of Peregrine approved a 1-for-100 reverse stock split effective March 1987. The reverse stock split entitled each shareholder of record at the close of business on March 12, 1987, to receive 1 share of common stock in exchange for every 100 shares of common stock held.
How can I receive SEC documents like the Form 10-K or 10-Q?
The SEC Filings button on the left under the "investors" section offers access to our SEC documents, or a hard copy can be mailed to you by submitting an Information Request form.
How can I receive Peregrine information materials?
To obtain an information pack, please submit an "Info Request" under the "investors" section.
Investor FAQs 
